PharmaNutra revenue and financials
In the fiscal year ended December 2025, PharmaNutra reported revenue of €132.16M (+13.78% year over year). Net income was €20M, a net margin of 15.1%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +13.78%
- 2025 vs 2024
- Net income growth
- +20.44%
- 2025 vs 2024
- Net margin
- 15.1%
- 2024: 14.3%
How PharmaNutra is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 18.4% a year on average over the last 5 years
Compound annual growth rate: from €56.77M in 2020 to €132.16M in 2025.
Revenue has grown for 9 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin fell from 27.8% to 22.0%
Operating income over revenue, 2022 → 2025: 5.8 percentage points.
Free cash flow equal to 64% of net income
Totals for fiscal years 2023–2025: free cash flow €31.44M, net income €49.44M.
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 132 | 116 | 101 | 83.1 | 68.1 | 56.8 | 53.7 | 46.8 | 37.8 | 33.0 |
| Cost of revenue | 65.4 | 56.9 | 52.1 | 41.1 | 36.0 | 30.3 | 30.9 | 27.3 | 22.2 | 20.3 |
| Gross profit | 66.8 | 59.2 | 48.6 | 41.9 | 32.2 | 26.5 | 22.8 | 19.5 | 15.6 | 12.7 |
| Selling, general and administrative | 32.7 | 26.7 | 22.5 | 17.2 | 12.1 | 9.9 | 9.5 | 7.6 | 5.8 | 5.1 |
| Research and development | 0.8 | 1.3 | 1.2 | 0.5 | — | — | — | — | — | — |
| Operating income | 29.1 | 27.4 | 23.0 | 23.1 | 18.3 | 14.2 | 12.1 | 11.2 | 8.8 | 6.2 |
| EBIT | 29.1 | 27.4 | 23.0 | 23.1 | 18.3 | 14.2 | 12.1 | 11.2 | 8.8 | 6.2 |
| EBITDA | 31.8 | 30.9 | 25.4 | 24.2 | 19.3 | 15.1 | 12.9 | 11.7 | 9.4 | 7.1 |
| Interest expense | 0.7 | 1.1 | 0.8 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
| Pre-tax income | 30.2 | 27.2 | 23.3 | 23.4 | 18.8 | 13.3 | 12.2 | 11.9 | 8.8 | 6.1 |
| Income tax | 10.3 | 10.6 | 10.4 | 8.4 | 5.0 | -0.8 | 3.7 | 3.3 | 2.7 | 2.2 |
| Net income | 20.0 | 16.6 | 12.8 | 15.0 | 13.8 | 14.1 | 8.5 | 8.6 | 6.0 | 3.9 |
| Net income to common shareholders | 20.0 | 16.6 | 12.8 | 15.0 | 13.8 | 14.1 | 8.5 | 8.6 | 6.0 | 3.9 |
| Basic EPS | 2.09 | 1.73 | 1.33 | 1.56 | 1.42 | 1.45 | 0.87 | 0.88 | 0.62 | 0.48 |
| Diluted EPS | 2.09 | 1.73 | 1.33 | 1.56 | 1.42 | 1.45 | 0.87 | 0.88 | 0.62 | 0.48 |
| Average shares (basic) | 9.6 | 9.6 | 9.7 | 9.7 | 9.7 | 9.7 | 9.7 | 9.7 | 9.7 | 8.1 |
| Average shares (diluted) | 9.6 | 9.6 | 9.7 | 9.7 | 9.7 | 9.7 | 9.7 | 9.7 | 9.7 | 8.1 |
| Dividend per share | 1.20 | 1.00 | 0.85 | 0.80 | 0.71 | 0.67 | 0.46 | 0.42 | 0.33 | — |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 40.5 | 33.2 | 37.2 | 31.9 | 35.7 | 26.5 | 32.2 | 27.4 | 32.7 | 23.8 | 28.8 | 21.9 |
| Cost of revenue | 19.4 | 17.2 | 19.2 | 34.1 | 16.3 | 14.3 | 15.8 | 13.2 | 15.1 | 12.8 | 14.9 | 12.0 |
| Gross profit | 21.1 | 16.0 | 18.0 | -2.2 | 19.4 | 12.2 | 16.4 | 14.2 | 17.6 | 11.0 | 13.9 | 9.9 |
| Selling, general and administrative | 9.8 | 9.6 | 9.2 | -10.1 | 7.8 | 7.3 | 8.3 | 6.1 | 6.2 | 6.1 | 7.2 | 4.8 |
| Research and development | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | — | — | — | — | — | — | — |
| Operating income | 10.0 | 5.2 | 7.6 | 7.1 | 9.8 | 3.8 | 6.7 | 6.6 | 10.2 | 3.9 | 5.4 | 4.6 |
| EBIT | 10.0 | 5.2 | 7.6 | 7.1 | 9.8 | 3.8 | 6.7 | 6.6 | 10.2 | 3.9 | 5.4 | 4.6 |
| EBITDA | 11.0 | 6.0 | 7.8 | 7.5 | 11.1 | 4.6 | 7.8 | 7.7 | 10.7 | 4.7 | 6.7 | 4.9 |
| Interest expense | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 |
| Pre-tax income | 9.9 | 5.3 | 8.2 | 7.6 | 10.4 | 4.1 | 6.4 | 6.5 | 10.2 | 4.0 | 5.6 | 4.5 |
| Income tax | 3.5 | 1.8 | 2.2 | 2.8 | 3.6 | 1.6 | 3.0 | 2.3 | 4.0 | 1.4 | 2.5 | 2.0 |
| Net income | 6.5 | 3.5 | 6.0 | 4.8 | 6.7 | 2.4 | 3.4 | 4.3 | 6.3 | 2.6 | 3.1 | 2.5 |
| Net income to common shareholders | 6.5 | 3.5 | 6.0 | 4.8 | 6.7 | 2.4 | 3.4 | 4.3 | 6.3 | 2.6 | 3.1 | 2.5 |
| Basic EPS | 0.68 | 0.36 | 0.63 | 0.50 | 0.72 | 0.25 | 0.36 | 0.44 | 0.66 | 0.27 | 0.32 | 0.26 |
| Diluted EPS | 0.68 | 0.36 | 0.63 | 0.50 | 0.72 | 0.25 | 0.36 | 0.44 | 0.66 | 0.27 | 0.32 | 0.26 |
| Average shares (basic) | 9.6 | 9.6 | 9.6 | 9.7 | 9.4 | 9.7 | 9.6 | 9.6 | 9.5 | 9.7 | 9.8 | 9.6 |
| Average shares (diluted) | 9.6 | 9.6 | 9.6 | 9.7 | 9.4 | 9.7 | 9.6 | 9.6 | 9.5 | 9.7 | 9.8 | 9.6 |
| Dividend per share | — | — | 1.20 | — | — | — | 1.00 | — | — | — | 0.85 | — |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 125 | 117 | 112 | 100 | 71.4 | 51.7 | 48.9 | 41.5 | 33.4 | 19.0 |
| Current assets | 72.9 | 65.0 | 58.7 | 58.7 | 55.5 | 40.4 | 37.2 | 34.2 | 26.6 | 13.0 |
| Cash and equivalents | 18.6 | 15.5 | 18.9 | 22.1 | 29.4 | 16.5 | 13.8 | 15.0 | 14.1 | 2.6 |
| Short-term investments | 12.0 | 13.5 | 6.2 | 4.8 | 4.5 | 4.3 | 5.1 | 0.9 | — | — |
| Receivables | 27.2 | 24.2 | 21.9 | 23.8 | 17.7 | 16.9 | 16.0 | 15.3 | 10.4 | 9.3 |
| Inventory | 8.9 | 6.9 | 8.2 | 5.3 | 2.9 | 1.9 | 1.9 | 2.2 | 1.9 | 1.1 |
| Net property, plant and equipment | 24.1 | 25.7 | 26.4 | 17.1 | 8.4 | 4.8 | 4.9 | 1.0 | 1.1 | 1.0 |
| Goodwill | 17.6 | 17.6 | 17.6 | 17.6 | 2.8 | 2.8 | 2.8 | — | 2.8 | 2.8 |
| Other intangible assets | 3.8 | 3.7 | 3.7 | 3.1 | 2.5 | 2.4 | 2.0 | 4.7 | 1.6 | 1.3 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Current liabilities | 31.0 | 27.3 | 27.6 | 25.8 | 16.7 | 11.1 | 16.3 | 13.0 | 9.7 | 9.6 |
| Accounts payable | 17.4 | 13.5 | 13.7 | 14.9 | 8.5 | 6.4 | 7.7 | 6.4 | 4.7 | 4.2 |
| Long-term debt | 14.4 | 18.1 | 22.2 | 13.6 | 5.0 | 0.3 | 1.1 | 1.8 | 3.0 | 1.7 |
| Total debt | 19.9 | 23.9 | 27.4 | 17.7 | 6.4 | 1.7 | 6.4 | 3.0 | 4.2 | 3.7 |
| Total liabilities | 54.0 | 55.3 | 58.0 | 49.2 | 26.3 | 14.0 | 20.7 | 17.0 | 14.3 | 12.3 |
| Total equity (incl. minority) | 71.2 | 62.1 | 54.4 | 50.9 | 45.1 | 37.7 | 28.1 | 24.4 | 19.1 | 6.7 |
| Retained earnings | 20.0 | 16.6 | 12.8 | 15.3 | 14.0 | 14.3 | 8.7 | 8.8 | 6.1 | 3.9 |
| Minority interest | -0.1 | -0.0 | 0.0 | — | — | — | — | — | — | — |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 121 | 128 | 125 | 120 | 116 | 123 | 117 | 116 | 112 | 115 | 112 | 107 |
| Current assets | 69.4 | 74.7 | 72.9 | 68.1 | 64.0 | 71.6 | 65.0 | 63.4 | 59.6 | 62.5 | 58.7 | 53.8 |
| Cash and equivalents | 7.2 | 21.2 | 18.6 | 14.8 | 9.1 | 23.9 | 15.5 | 17.8 | 15.5 | 15.5 | 18.9 | 9.6 |
| Short-term investments | 7.9 | 7.8 | 12.0 | 7.2 | 6.6 | 6.8 | 13.5 | 6.6 | 6.3 | 6.1 | 6.2 | 5.1 |
| Receivables | 36.0 | 28.8 | 27.2 | 27.7 | 38.6 | 32.4 | 24.2 | 25.1 | 25.8 | 26.7 | 21.9 | 25.4 |
| Inventory | 9.4 | 8.5 | 8.9 | 10.2 | 9.8 | 8.4 | 6.9 | 8.0 | 7.6 | 8.2 | 8.2 | 7.8 |
| Net property, plant and equipment | 24.3 | 24.1 | 24.1 | 24.3 | 24.8 | 25.3 | 25.7 | 25.2 | 25.4 | 26.0 | 26.4 | 27.0 |
| Goodwill | 17.6 | — | 17.6 | — | — | — | 17.6 | — | 17.6 | — | 17.6 | — |
| Other intangible assets | 7.2 | 24.7 | 3.8 | 24.4 | 23.9 | 23.6 | 3.7 | 23.6 | 3.8 | 22.9 | 3.7 | 22.6 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 | — | — | 0.0 | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 |
| Current liabilities | 33.9 | 31.4 | 31.0 | 31.1 | 31.0 | 31.3 | 27.3 | 28.1 | 28.3 | 29.1 | 27.6 | 26.5 |
| Accounts payable | 18.0 | 17.5 | 17.4 | 17.7 | 19.5 | 16.8 | 13.5 | 15.7 | 11.7 | 14.7 | 13.7 | 15.2 |
| Long-term debt | 12.3 | 13.3 | 14.4 | 14.9 | 17.0 | 18.7 | 18.1 | 19.4 | 20.2 | 21.0 | 22.2 | 20.0 |
| Total debt | 18.3 | 19.0 | 19.9 | 20.9 | 22.1 | 24.1 | 23.9 | 24.3 | 25.4 | 26.5 | — | — |
| Total liabilities | 51.4 | 53.7 | 54.0 | 53.7 | 54.4 | 58.9 | 55.3 | 56.7 | 57.0 | 58.4 | 58.0 | 56.0 |
| Total equity (incl. minority) | 69.5 | 74.5 | 71.2 | 66.1 | 61.2 | 64.5 | 62.1 | 58.9 | 54.8 | 57.0 | 54.4 | 51.3 |
| Retained earnings | 9.9 | 3.5 | 20.0 | 14.0 | 9.2 | — | 16.6 | 23.4 | 9.1 | 2.9 | 12.8 | 10.0 |
| Minority interest | -0.1 | -0.1 | -0.1 | -0.0 | 0.0 | — | — | — | — | — | — | — |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 19.6 | 20.4 | 12.1 | 17.5 | 20.4 | 11.8 | 12.0 | 6.4 | 5.7 | 5.9 |
| Depreciation and amortization | 3.2 | 3.5 | 2.4 | 1.1 | 1.0 | 0.9 | 0.8 | 0.6 | 0.6 | 0.9 |
| Capital expenditure | -3.1 | -4.3 | -13.2 | -26.2 | -5.0 | -1.7 | -4.9 | -0.8 | -0.9 | -2.2 |
| Investing cash flow | -3.4 | -2.2 | -14.7 | -26.7 | -5.5 | -0.6 | -5.3 | -1.3 | -1.4 | -1.9 |
| Financing cash flow | -13.1 | -21.6 | -0.5 | 1.9 | -1.9 | -8.5 | -9.3 | -5.1 | 7.7 | -2.2 |
| Dividends paid | -9.6 | -8.2 | -7.7 | -6.9 | -6.5 | -4.5 | -4.8 | -3.2 | -1.7 | -1.3 |
| Share repurchases | -1.3 | -0.6 | -1.7 | -2.4 | — | -0.0 | — | — | -0.5 | -0.0 |
| Debt issued | 2.6 | 0.6 | 11.0 | 15.4 | 5.4 | 0.0 | — | — | 1.3 | — |
| Debt repaid | -6.3 | -6.1 | -0.7 | -4.0 | -0.7 | -4.7 | -0.3 | -1.2 | — | -1.0 |
| Net change in cash | 3.1 | -3.4 | -3.1 | -7.4 | 13.0 | 2.7 | -2.6 | 0.0 | 12.0 | 1.7 |
| Free cash flow | 16.4 | 16.2 | -1.2 | -8.7 | 15.4 | — | — | — | — | — |
| Levered free cash flow | 15.2 | 12.7 | 2.2 | -14.7 | 11.4 | 5.5 | 5.4 | 3.3 | 3.6 | 4.0 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.8 | 2.0 | 11.6 | 8.3 | -2.4 | 2.1 | 6.4 | 6.2 | 10.1 | -2.3 | 8.9 | 3.0 |
| Depreciation and amortization | 1.4 | 0.8 | 0.7 | 0.5 | 1.2 | 0.8 | 1.2 | 0.8 | 0.8 | 0.8 | 1.3 | 0.4 |
| Capital expenditure | -1.4 | -1.0 | -0.9 | -0.8 | -0.7 | -0.7 | -1.8 | -0.9 | -0.8 | -0.8 | -1.0 | -2.5 |
| Investing cash flow | 1.1 | -2.0 | -1.6 | -0.9 | -0.8 | -0.0 | -1.3 | -0.9 | -0.1 | 0.2 | -1.6 | -3.0 |
| Financing cash flow | -12.2 | 2.6 | -6.0 | -1.7 | -11.7 | 6.3 | -7.4 | -3.0 | -9.9 | -1.3 | 2.1 | -0.8 |
| Dividends paid | -11.5 | — | 0.0 | 0.0 | -9.6 | — | 0.0 | — | -8.2 | — | — | — |
| Share repurchases | — | 0.0 | -0.9 | 0.0 | -0.4 | -0.2 | -0.0 | -0.2 | -0.3 | — | -0.0 | — |
| Debt issued | 0.3 | 0.2 | 2.2 | 0.4 | 0.5 | 0.9 | 0.6 | -0.0 | 0.0 | 0.1 | -0.0 | -2.1 |
| Debt repaid | -1.0 | -1.6 | -2.6 | -1.5 | -2.4 | -1.1 | -0.8 | -2.5 | -1.6 | -1.1 | 2.4 | 2.0 |
| Net change in cash | -13.9 | 2.6 | -10.1 | 19.7 | -14.9 | 8.3 | -2.3 | 2.3 | 0.1 | -3.4 | 9.4 | -0.7 |
| Free cash flow | -4.2 | 1.0 | 10.7 | 7.5 | -3.2 | 1.4 | 4.6 | 5.3 | 9.3 | -3.1 | 7.9 | 0.5 |
| Levered free cash flow | -0.0 | 0.4 | 8.4 | 6.3 | -1.0 | 0.9 | 5.1 | 4.2 | 8.8 | -5.3 | 9.5 | 1.3 |
Financial statements of similar companies
Companies in the group: same industry, similar size
